ORION Biotech Catalyst Calendar
Menu
Skip to company history
COMPANY HISTORY / RETAINED ORIGINAL SOURCES

What did the company say,
and what came next?

In the reviewed release recorded , ORION retains 2 historical announcement records as of for CRISPR Therapeutics (CRSP). Read the original sources and their publication dates below or inspect the dated catalog.

Last updated: · reviewed catalog release, not a fresh source check

  1. 1 Choose one ticker
  2. 2 Read the evidence
  3. 3 Keep a starting point

10 companies · 24 retained records · Reviewed 2026-09-26T07:20:44Z.

What did CRSP disclose about Exagamglogene autotemcel (exa-cel / CASGEVY)?

CRISPR Therapeutics · Exa-cel US review for sickle cell disease · 2 retained source records as of .

Earlier selected statement

Read the source context →

Stated timing: 2023-12-08

Source published · Original announcement. ORION first recorded .

Later selected disclosure

Read the source context →

Source published · Original announcement. ORION first recorded .

Follow-up research question

Which indication and age group were approved, and how does that differ from the separate thalassemia application?

YOUR PRIVATE STARTING POINT

Compare with what you saved.

Save a milestone to your account’s Notebook. Reopen its original snapshot here and compare with this reviewed catalog. Email subscriptions use a separate opt-in.

Sign inManage Notebook allowance
Source index · readable without the interactive view

CRISPR Therapeutics (CRSP)

Exa-cel US review for sickle cell disease

  1. Exa-cel FDA application acceptance

    CRISPR and Vertex reported a December 8, 2023 FDA target date for the sickle cell disease application. The separate thalassemia application had a different target and is not combined into this milestone.

    Stated timing: 2023-12-08

    Original announcement.

    Source published (published_at)
    Event effective (effective_at)
    UNAVAILABLE
    ORION first seen (first_seen_at)
    ORION ingested (ingested_at)
  2. Vertex and CRISPR: CASGEVY US SCD approval

    Vertex and CRISPR announced FDA approval of CASGEVY for sickle cell disease in patients aged 12 years and older with recurrent vaso-occlusive crises.

    Original announcement.

    Source published (published_at)
    Event effective (effective_at)
    ORION first seen (first_seen_at)
    ORION ingested (ingested_at)

Scope

These selected company announcements preserve publication dates separately from ORION’s later recording times. Registry completion dates and follow-up research questions are separate from company announcements; this historical release does not establish current guidance or continuous monitoring.

Coverage & method → · Corrections · Catalog manifest

THE WEEKLY RESEARCH NOTE

Keep the original sources close.

Sign up for ORION’s free English research email. Company-specific monitoring is separate.

Checking email signup availability…